Shandong Boan Biotechnology Company., Limited. Class H (HK:6955) has released an update.
Shandong Boan Biotechnology has announced the acceptance of its Biologics License Application in China for Aflibercept Intravitreous Injection, a promising treatment for eye diseases causing visual impairment and blindness. The treatment, similar to the widely successful EYLEA, has shown comparable safety and efficacy in clinical trials, indicating its potential in the growing market for ophthalmic drugs. In partnership with Ocumension Therapeutics, the company aims to expedite the approval and commercialization process in China, addressing urgent patient needs and strengthening its position in biological products.
For further insights into HK:6955 stock, check out TipRanks’ Stock Analysis page.
